Upcoming regulatory changes to create new opportunity for specialized offerings.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
2
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
